UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________________________________
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the month of April, 2012
Commission File Number ________________
Novogen Limited
(Translation of registrant’s name into English)
140 Wicks Road, North Ryde, NSW, Australia
(Address of principal executive office)
___________________________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(l): o
Note: Regulation S-T Rule 101 (b)( I) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule lO1(b)(7): o
Note: Regulation S-T Rule l01(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule l2g3-2(b) under the Securities Exchange Act of 1934. Yes o No x
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Novogen Limited
(Registrant)
/s/ Ron Erratt
Ronald Lea Erratt
Company Secretary
Date 5 April, 2012
ASX & MEDIA RELEASE
5 APRIL, 2012
NOVOGEN INTERIM DIVIDEND INFORMATION
Novogen today announces an interim dividend of 90% of the Units received from its majority
owned subsidiary Marshall Edwards Inc, through its Rights Offering.
The dividend will be paid to all Novogen shareholders on a 3 Rights for 40 Shares held basis. The
dividend will be paid to all Novogen shareholders who are recorded on the register at 5.00 pm on
18 April 2012. Shareholders will not be entitled to receive a fraction of a right and the number of
Rights that shareholders will receive will be rounded down to the nearest whole number. The
total number of Rights to be despatched to shareholders under the dividend will be 7,659,442.
The dividend will be despatched on 20 April 2012.
About Novogen Limited
Novogen Limited is an Australian biotechnology company based in Sydney, Australia. Novogen
conducts research and development on oncology therapeutics through its subsidiary, Marshall
Edwards, Inc., and is developing glucan technology through its subsidiary, Glycotex, Inc. More
information on the Novogen group of companies can be found at www.novogen.com.